Top 10 Considerations for Global Stability Study Design
Determine the ICH climatic zones applicable to your target markets and ensure real-time data generation accordingly:
Click to read the full article.
Determine the ICH climatic zones applicable to your target markets and ensure real-time data generation accordingly:
Click to read the full article.
One of the most common causes for WHO or CDSCO rejections is the absence of Zone IVb data (30°C/75% RH). Companies often submit only Zone II or III data, assuming ICH Q1A coverage is sufficient.
Click to read the full article.
Start by developing a core protocol aligned with ICH Q1A–Q1F, covering the essential elements required by most regulatory agencies:
Click to read the full article.
ICH Q12, titled “Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management,” introduces tools to facilitate post-approval changes without triggering full variation filings. The guidance includes:
Click to read the full article.
A mid-sized European pharmaceutical company planned to launch a solid oral generic in both:
Click to read the full article.
Stability testing must be consistent, reproducible, and auditable. Discrepancies in SOPs can lead to:
Click to read the full article.
Stability testing supports product shelf life, storage conditions, and labeling claims. If packaging and labeling used during studies don’t match the intended commercial presentation, regulators may question data relevance. Additionally:
Click to read the full article.
Stability data supports critical product decisions, such as:
Click to read the full article.
Different regions interpret and apply ICH stability principles with varying levels of strictness. Without a harmonized documentation plan, issues may arise such as:
Click to read the full article.
Reviewers frequently challenge the relevance of selected storage conditions, especially for global submissions involving diverse climatic zones.
Click to read the full article.
